ERBB2 and neoplasm: In that study, treatment of CT26/HER2 tumor-bearing mice with anti-PD-L1 antibodies failed to show any effects on Ag-specific CTL induction and tumor growth inhibition, suggesting that PD-L1 is not associated with the inhibition of Ag-specific CTL induction in the CT26/HER2 model.